Summary by Futu AI
HUTCHMED ANNOUNCED A COLLABORATION WITH JIANGSU HENRI PHARMACEUTICAL CO., LTD. (HENRI PHARMACEUTICALS) TO LAUNCH PHASE II/III CLINICAL TRIALS FOR INITIATING PANCREATIC DUCT CANCER. The trial will evaluate the combined treatment of Xanthinic and Hengrei's PD-1 antibody, Carrilobulmonal, protein-bound retinol, and Gizitabamine. The first participant received treatment on May 8, 2024. The multi-center, randomized, open-label, positive-controlled study was designed to evaluate the efficacy and safety of the new combination therapy in patients with metastatic pancreatic cancer in adults. The study will recruit about 500 patients, with the primary endpoint being total survival. Dr. Su Ju-guo, CEO and Chief Scientific Officer of Wah Wong Pharmaceuticals, said he hoped the collaboration could bring innovative treatment options to patients. SOFANTINE HAS BEEN LISTED ON THE CHINESE MARKET AS SUTEDA®, CARILIZU HAS BEEN APPROVED FOR MULTIPLE INDICATIONS IN CHINA AND HAS BEEN INCLUDED IN THE PHARMACEUTICAL CATALOGUE.